Three ways to work with the FDA for better patient-focused trials
Putting patients at the center of drug development allows us to design more efficient clinical trials that yield better data about a product’s risks and benefits. Companies that collaborate with the FDA can get direct feedback on their methodology and help build consensus on patient-relevant outcomes that might be accepted as proof of efficacy and safety.
This article covers three useful practices for getting the most out of your collaboration.
Related Insights
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Blog
Breaking through complex regulations and science speak – thinking “patients first” in lay language summary development
Jun 22, 2021
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Article
The technologies that are reshaping biotherapeutics manufacturing, an EU perspective
Jul 6, 2023
Whitepaper
How to prepare for Policy 0070: Challenges and opportunities for clinical data publication in the EU
Jun 28, 2023
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Webinar
Adaptive strategies for more efficient, data-rich and patient-friendly trials
May 28, 2023
Blog
New FDA biosimilars guidance: CES waiver pathway aligns with global regulatory approaches
Nov 11, 2025
Related Insights
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Blog
Breaking through complex regulations and science speak – thinking “patients first” in lay language summary development
Jun 22, 2021
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Article
The technologies that are reshaping biotherapeutics manufacturing, an EU perspective
Jul 6, 2023
Whitepaper
How to prepare for Policy 0070: Challenges and opportunities for clinical data publication in the EU
Jun 28, 2023
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Webinar
Adaptive strategies for more efficient, data-rich and patient-friendly trials
May 28, 2023
Blog
New FDA biosimilars guidance: CES waiver pathway aligns with global regulatory approaches
Nov 11, 2025